DDInter1853 DDInter660
Tretinoin, also known as all-trans-retinoic acid (ATRA), is a naturally occurring derivative of [vitamin A] (retinol). It is an oxidation product in the physiological pathway of vitamin A metabolism. In human circulation, tretinoin is normally found at very low concentrations, approximately 4 to 14 nmol/L. Tretinoin exhibits anti-inflammatory, antineoplastic, antioxidant, and free radical-scavenging activities. It has been used in dermatology for many years to treat various skin conditions ranging from acne to wrinkles [A257474,A258185] and activates nuclear receptors to regulate epithelial cell growth and differentiation.[A257474,A257629,A257609] Tretinoin is given orally to treat acute promyelocytic leukemia and topically to treat skin conditions such as acne.[L45389,L34869,L45384]
Eravacycline, known as _Xerava_ by Tetraphase Pharmaceuticals, is a fully synthetic fluorocycline antibiotic of the tetracycline class with activity against clinically significant gram-negative, gram-positive aerobic, and facultative bacteria. This includes most of those bacteria resistant to cephalosporins, fluoroquinolones, β-lactam/β-lactamase inhibitors, multidrug-resistant strains, and carbapenem-resistant Enterobacteriaceae, and the majority of anaerobic pathogens . It was first approved by the FDA on August 27, 2018 . Eravacycline has demonstrated superior potency to that of antibiotics that are currently being marketed for intraabdominal infections .
Tretinoin {u} (Compound) resembles {v} (Compound) Isotretinoin
Isotretinoin {u} may lead to a major life threatening interaction when taken with {v} Eravacycline
Tretinoin {u} (Compound) resembles {v} (Compound) Isotretinoin
Isotretinoin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Idelalisib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Eravacycline
Tretinoin {u} (Compound) binds {v} (Gene) CYP3A5
CYP3A5 {u} (Gene) is bound by {v} (Compound) Clarithromycin
Clarithromycin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Eravacycline
Tretinoin {u} (Compound) resembles {v} (Compound) Isotretinoin
Isotretinoin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Methoxsalen
Methoxsalen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eravacycline
Tretinoin {u} (Compound) binds {v} (Gene) CYP3A5
CYP3A5 {u} (Gene) is bound by {v} (Compound) Enzalutamide
Enzalutamide {u} may lead to a major life threatening interaction when taken with {v} Eravacycline
Tretinoin {u} (Compound) resembles {v} (Compound) Acitretin
Acitretin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Methoxsalen
Methoxsalen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eravacycline
Tretinoin {u} (Compound) resembles {v} (Compound) Acitretin
Acitretin {u} may lead to a major life threatening interaction when taken with {v} Isotretinoin
Isotretinoin {u} may lead to a major life threatening interaction when taken with {v} Eravacycline
Tretinoin {u} (Compound) resembles {v} (Compound) Isotretinoin
Isotretinoin {u} may lead to a major life threatening interaction when taken with {v} Bexarotene
Bexarotene {u} may lead to a major life threatening interaction when taken with {v} Eravacycline
Tretinoin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Methoxsalen
Methoxsalen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eravacycline
Tretinoin {u} (Compound) resembles {v} (Compound) Isotretinoin
Isotretinoin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lumacaftor
Lumacaftor {u} may lead to a major life threatening interaction when taken with {v} Eravacycline
Tretinoin (Compound) resembles Isotretinoin (Compound) and Iso
Tretinoin (Compound) resembles Isotretinoin (Compound) and Isotretinoin may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a minor interaction that can limit clinical effects when taken with Eravacycline
Tretinoin (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Clarithromycin (Compound) and Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Eravacycline
Tretinoin (Compound) resembles Isotretinoin (Compound) and Isotretinoin may cause a moderate interaction that could exacerbate diseases when taken with Methoxsalen and Methoxsalen may cause a moderate interaction that could exacerbate diseases when taken with Eravacycline
Tretinoin (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Enzalutamide (Compound) and Enzalutamide may lead to a major life threatening interaction when taken with Eravacycline
Tretinoin (Compound) resembles Acitretin (Compound) and Acitretin may cause a moderate interaction that could exacerbate diseases when taken with Methoxsalen and Methoxsalen may cause a moderate interaction that could exacerbate diseases when taken with Eravacycline
Tretinoin (Compound) resembles Acitretin (Compound) and Acitretin may lead to a major life threatening interaction when taken with Isotretinoin and Iso
Tretinoin (Compound) resembles Isotretinoin (Compound) and Isotretinoin may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Eravacycline
Tretinoin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Methoxsalen (Compound) and Methoxsalen may cause a moderate interaction that could exacerbate diseases when taken with Eravacycline
Tretinoin (Compound) resembles Isotretinoin (Compound) and Isotretinoin may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor and Lumacaftor may lead to a major life threatening interaction when taken with Eravacycline